Department of Health and Social Care (DHSC) has issued a medicine supply notification for Primidone (Aspire Pharma) 50mg tablets.


Tier 2 – medium impact

Date of issue 27th March 2023

Primidone (Aspire Pharma) 50mg tablets are out of stock until w/c 24th April 2023
Teva brand of primidone 50mg tablets remain available and will be able to support increased demand.
Primidone is a category 1 anti-epileptic drug and indicated for use in essential tremor and epilepsy.

As primidone is a category 1 anti-epileptic drug, clinically relevant differences between different manufacturers’ products might occur, even when the pharmaceutical forms are the same and bioequivalence has been shown. It is recommended that patients are maintained on a specific manufacturer’s product. Where this is not possible, as in the case of a shortage, patients should be monitored for worsening of symptoms or side effects after a switch.

A copy of this medicine supply notification, including further information for pharmacy teams, has been sent to all pharmacy NHS email addresses.

DHSC and NHSE/I have now launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. The contents of these MSNs can now be viewed on the Tool.

The Tool also details any changes to resupply dates and updates to the entries.

To access the Tool you will need  an NHS email address. Once set up and logged in, you will be able to access it online.

New shortages not listed on the SPS website, can be reported using our shortage reporting tool.

The post Medicine Supply Notification: Primidone (Aspire Pharma) 50mg tablets appeared first on PSNC Website.